About Wuhan Hiteck Biological Pharma Company

The company is a high-tech biopharmaceutical company with the goal of building an outstanding biopharmaceutical enterprise in China. It was listed on the Shenzhen Stock Exchange GEM on August 8, 2017. The main business is the production and sale of bioengineered products and freeze-dried powder needles; the import and export business of the company's products and technology. The company's main business is the manufacture and sale of macromolecular biopharmaceuticals, small-molecule chemicals, APIs and pharmaceutical intermediates, and also provides CRO, CMO and CDMO technical services for preparations and APIs to domestic and foreign pharmaceutical companies. The company's main products are injectable rat nerve growth factor, injectable epneimine, injectable tedizolamide phosphate, antiviral drugs, injectable roxatidine hydrochloride acetate, injectable esomeprazole sodium, pentoxifylline injections; pharmaceutical research; CRO clinical, etc. Company honors: Famous trademarks in Wuhan, top ten new private economy enterprises, top ten private economy enterprises, contract-honoring and trustworthy enterprises, enterprises with harmonious labor relationships, etc. It has won honors such as “China's Top 50 Pharmaceutical Industry Growth Companies for the Year 2022 - 2023”, “China's Pharmaceutical Industry Law-abiding and Honest Enterprise”, “2023 China Chegu Excellent Enterprise for Recruiting Talents”, “Outstanding Small and Medium Investors Interactive Award”, and on the Wuhan Top 50 Private Enterprise Science and Technology Innovation List.